A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Exclusion Criteria

• •Diagnosis of malignant diseases other than pancreatic cancer within 5 years prior to first administration (excluding cured skin basal cell carcinoma, squamous carcinoma of the skin, and/or resected carcinoma in situ);
• •Medical conditions that affect absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorders, etc.);
• •Patients with brain metastases or pial metastases;
• •Patients with a clear past history of neurological or psychiatric disorders, including epilepsy or dementia;
• •Comorbidities (e.g., severe or uncontrolled hypertension, severe diabetes, and/or thyroid disease) that, in the investigator's judgment, seriously endanger patients' safety or prevent them from completing the study;
• •The patient was currently participating in an interventional clinical study or had been treated with another study drug or study device in the 4 weeks prior to initial dosing;
• •The patient had a history of organ transplantation;
• •Concurrent administration of drugs that may prolong QTc and/or induce Tdp;
• •Patients also take drugs that affect drug metabolism;
• •HIV infection or acute or chronic viral hepatitis (hbSAG positive, HBV-DNA load ≥500IU/ml and/or HCV antibody positive);
• •Excluded patients with serious cardiovascular disease, including grade ≥II cardiac dysfunction (NYHA criteria);
• •Patients with severe gastrointestinal dysfunction (bleeding, infection, obstruction, or diarrhea greater than grade 1) were excluded;
• •Patients with abnormal coagulation function, bleeding tendency, or receiving thrombolytic or anticoagulant therapy were excluded;
• •Patients with a severe arterial thromboembolism event within 6 months were excluded;
• •Excluding women who are pregnant or breast-feeding.